The latest market price of Pitobrutinib/Pitobrutinib in 2025

Pirtobrutinib is mainly used in clinical applications in the field of B-cell lymphoma, especially relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after multiple lines of treatment. As a non-covalent BTK inhibitor, it can continue to exert its inhibitory effect after the failure of traditional BTK inhibitors, bringing therapeutic opportunities to drug-resistant patients. In actual use, pitubrutinib is often taken in the form of oral tablets at a fixed dose every day to facilitate long-term management by patients.

Judging from the market situation, the original version of the drug has been launched in China, but it has not yet been included in the national medical insurance directory, so patients need to purchase it at their own expense. At present, the common specifications in domestic pharmacies are 100mg, 14 tablets and 4 plates. The price per box is more than 40,000 yuan, which belongs to the category of high-priced targeted drugs. For patients undergoing long-term treatment, this price poses greater financial pressure.

In overseas markets, the original drug of Pitobrutinib is available in European and American versions, with specifications including 50mg 30 tablets and 100mg 60 tablets. Each box sells for nearly 100,000 yuan, and the price is even higher. This is related to the R&D investment, patent protection and marketing cycle of the drug. It is also the cost structure characteristic faced by most imported original drugs in the early stage.

It is worth noting that generic versions of pitubrutinib have appeared in some overseas countries and regions. For example, the generic version of 50mg*30 tablets produced by a Lao pharmaceutical factory has basically the same ingredients as the original drug, but the price is significantly lower. Each box may cost more than 2,000 yuan, and the price will be adjusted due to exchange rate fluctuations. This type of generic drugs has been used clinically in some regions, but has not yet been approved for marketing in mainland China. Therefore, patients must pay attention to the legality of drug sources and drug quality if they obtain them through cross-border channels.

Reference materials:https://go.drugbank.com/drugs/DB17472